- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Financial Performance: Epigral Limited reported a 37% increase in Q3 FY25 revenue to INR 649 crores, up from INR 474 crores year-on-year, driven primarily by an 11% growth in sales volume, especially within the Derivatives and Specialty sectors. The EBITDA surged 49% to INR 183 crores, with margins improving to 28% from 26% in Q3 FY24. The PAT skyrocketed 110% to INR 104 crores, enhancing the PAT margin to 16%. For the nine-month period, revenue also rose by 37% to INR 1,934 crores, underpinned by a 15% sales volume hike.
Future Outlook and Growth Drivers: Management emphasized a robust domestic demand compared to a slower global market, predicting continued growth in chemicals, particularly CPVC resin and Epichlorohydrin as they plan to double production capacities in FY27. The successful commissioning of ongoing projects and a focus on value-added import substitutes are expected to bolster revenues moving forward.
Order Book and Operational Updates: Capacity utilization stood at 81% in Q3 FY25, with expectations that new commissioning projects will contribute significantly in FY26. Notably, the chlorotoluene project is in its final commissioning phase, anticipated to start generating revenue in the second half of FY26.
Analyst Q&A Insights: Analysts questioned revenue projections and EBITDA margins. Management clarified that gross margins improved due to better realizations in caustic soda, while increased operational costs slightly impacted flat EBITDA margins. The conversation highlighted competitors' potential market entry but reassured confidence in demand absorption due to the growing market size for CPVC.
Market or Regulatory Updates: The call mentioned potential supply pressure from new market entrants, emphasizing the strategic focus on increasing domestic production capacity amid regulatory developments such as antidumping duties on PVC.
Strategic Focus Areas: The management maintains a strong growth trajectory, leveraging diversification and continuous CAPEX to stabilize revenues and enhance stakeholder value.
Investor Insight: The strong financial results, expansion strategy, and positive market outlook suggest a favorable position for investors, possibly indicating a ‘buy’ scenario, especially with robust growth prospects across key segments despite emerging competition.